Purpose Many women with hormone receptor-positive breast cancer discontinue effective
aromatase inhibitor (AI) treatment due to joint symptoms. Methods We conducted a single …

Aromatase inhibitors (AIs) are widely prescribed for post-menopausal hormone receptor-
positive breast cancer; however, musculoskeletal symptoms limit their tolerability. The …

Purpose Adherence to aromatase inhibitor (AI) therapy for early-stage breast cancer is
limited by AI-associated musculoskeletal symptoms (AIMSS). Duloxetine is US Food and …

Purpose Aromatase inhibitors (AIs) improve survival in postmenopausal women with
hormone-sensitive breast cancer, but can cause joint pain and stiffness. The purpose of the …

Objective To define the musculoskeletal syndrome associated with use of aromatase
inhibitors (AIs), specifically, to describe its incidence, time to onset, risk factors, and clinical …

Background Aromatase inhibitor therapy is often effective for breast cancer, yet it can be
accompanied by musculoskeletal pain and stiffness. This prevalence assessment aimed to …

Background: Aromatase inhibitors (AIs) have been established as successful adjuvant
therapy for breast cancer survivors. Unfortunately, nearly half of women taking AIs report …

More than a third of breast cancer patients undergoing aromatase inhibitor (AI) treatment
report joint pain. We conducted a longitudinal study to characterize the course of AI-induced …

Background: Although arthralgia is a known adverse effect of aromatase inhibitor (ai)
treatment in postmenopausal breast cancer patients, few studies have carried out a …

Abstract Purpose Aromatase inhibitors (AIs) are increasingly used as adjuvant treatment of
postmenopausal women with hormone receptor-positive breast cancer. AIs are commonly …